5,881 reports of this reaction
4.2% of all NIVOLUMAB reports
#3 most reported adverse reaction
OFF LABEL USE is the #3 most commonly reported adverse reaction for NIVOLUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 5,881 FDA adverse event reports linking NIVOLUMAB to OFF LABEL USE. This represents approximately 4.2% of all 139,909 adverse event reports for this drug.
NIVOLUMAB has an overall safety score of 89 out of 100. Patients taking NIVOLUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among NIVOLUMAB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for NIVOLUMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 5,881 FDA reports for NIVOLUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.2% of all adverse event reports for NIVOLUMAB, making it one of the most commonly reported side effect.
If you experience off label use while taking NIVOLUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.